![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
The relationship between sustained virological response and plasma concentrations of faldaprevir or BI 207127 in HCV GT-1-infected patients in SOUND-C2
|
|
|
Reported by Jules Levin
EASL 2013 April 24-28 Amsterdam
Stephen Olson,1 Kyle Baron,2 Matthew Riggs,2 Wulf O Böcher,3 Federico J Mensa1
1Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA; 2Metrum Research Group LLC, Tariffville, CT, USA; 3Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany
![EASL1.gif](../images/051913/051813-2/EASL1.gif)
![EASL2.gif](../images/051913/051813-2/EASL2.gif)
![EASL3.gif](../images/051913/051813-2/EASL3.gif)
![EASL4.gif](../images/051913/051813-2/EASL4.gif)
![EASL5.gif](../images/051913/051813-2/EASL5.gif)
![EASL6.gif](../images/051913/051813-2/EASL6.gif)
![EASL7.gif](../images/051913/051813-2/EASL7.gif)
![EASL8.gif](../images/051913/051813-2/EASL8.gif)
![EASL9.gif](../images/051913/051813-2/EASL9.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|